GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC: Form 990, tax year 2025

View the entire original 990 at ProPublica ↗

Organization
GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (EIN 13-4128413)
Tax period
2025-01-01 to 2025-12-31
Filed
2026-10-14
IRS object ID
202622879349301722
Schema version
2025v4.2
Source
Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header ReturnHeader

FieldValueIRS element (for citing)
Return2026-10-14T12:20:37+00:00ReturnTs
Tax Period End2025-12-31TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

FieldValueIRS element (for citing)
Preparer Firm EIN135381590PreparerFirmEIN

Preparer Firm Name PreparerFirmName

FieldValueIRS element (for citing)
Business Name Line1BDO USABusinessNameLine1Txt

Preparer US Address PreparerUSAddress

FieldValueIRS element (for citing)
Address Line1200 PARK AVE 38TH FLOORAddressLine1Txt
CityNEW YORKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP10166ZIPCd
FieldValueIRS element (for citing)
Return Type990ReturnTypeCd
Tax Period Begin2025-01-01TaxPeriodBeginDt

Filer Filer

FieldValueIRS element (for citing)
EIN134128413EIN

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INCBusinessNameLine1Txt
FieldValueIRS element (for citing)
Business Name ControlGLOBBusinessNameControlTxt
Phone2122277540PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line180 PINE STREET FL 20AddressLine1Txt
CityNEW YORKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP10005ZIPCd

Business Officer BusinessOfficerGrp

FieldValueIRS element (for citing)
PersonMELVIN SPIGELMANPersonNm
Person TitlePRESIDENT/CEOPersonTitleTxt
Signature2026-10-14SignatureDt
Discuss With Paid PreparerYes (true)DiscussWithPaidPreparerInd

Preparer Person PreparerPersonGrp

FieldValueIRS element (for citing)
Preparer PersonCHRISTINA PATTENPreparerPersonNm
PTINP01972759PTIN
Phone2128858000PhoneNum
Preparation2026-10-01PreparationDt
FieldValueIRS element (for citing)
Tax2025TaxYr

Form 990 IRS990

Doing Business As Name DoingBusinessAsName

FieldValueIRS element (for citing)
Business Name Line1TB ALLIANCEBusinessNameLine1Txt

Principal Ofcr Business Name PrincipalOfcrBusinessName

FieldValueIRS element (for citing)
Business Name Line1MELVIN SPIGELMANBusinessNameLine1Txt

US Address USAddress

FieldValueIRS element (for citing)
Address Line180 PINE STREET FL 20AddressLine1Txt
CityNEW YORKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP10005ZIPCd
FieldValueIRS element (for citing)
Gross Receipts$76,899,215GrossReceiptsAmt
Group Return For AffiliatesfalseGroupReturnForAffiliatesInd
Organization501c3Yes (X)Organization501c3Ind
Website AddressWWW.TBALLIANCE.ORGWebsiteAddressTxt
Type Of Organization CorpYes (X)TypeOfOrganizationCorpInd
Formation2000FormationYr
Legal Domicile StateDELegalDomicileStateCd
Activity Or MissionTO ACCELERATE THE DISCOVERY & DEVELOPMENT OF NEW DRUGS TO FACILITATE THE CONTROL OF TUBERCULOSIS THROUGHOUT THE WORLD AND THE ACCESSIBILITY OF THESE DRUGS TO THE GLOBAL COMMUNITY.ActivityOrMissionDesc
Voting Members Governing Body11VotingMembersGoverningBodyCnt
Voting Members Independent10VotingMembersIndependentCnt
Total Employee49TotalEmployeeCnt
Total Volunteers11TotalVolunteersCnt
Total Gross UBI$0TotalGrossUBIAmt
PY Contributions Grants$52,737,212PYContributionsGrantsAmt
CY Contributions Grants$41,898,401CYContributionsGrantsAmt
PY Program Service Revenue$0PYProgramServiceRevenueAmt
CY Program Service Revenue$0CYProgramServiceRevenueAmt
PY Investment Income$9,675,203PYInvestmentIncomeAmt
CY Investment Income$7,946,317CYInvestmentIncomeAmt
PY Other Revenue$1,320,142PYOtherRevenueAmt
CY Other Revenue$2,700,338CYOtherRevenueAmt
PY Total Revenue$63,732,557PYTotalRevenueAmt
CY Total Revenue$52,545,056CYTotalRevenueAmt
PY Grants And Similar Paid$359,938PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid$299,510CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members$0PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members$0CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid$17,962,003PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid$17,878,606CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns$0PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns$0CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense$1,114,379CYTotalFundraisingExpenseAmt
PY Other Expenses$43,186,842PYOtherExpensesAmt
CY Other Expenses$35,713,220CYOtherExpensesAmt
PY Total Expenses$61,508,783PYTotalExpensesAmt
CY Total Expenses$53,891,336CYTotalExpensesAmt
PY Revenues Less Expenses$2,223,774PYRevenuesLessExpensesAmt
CY Revenues Less Expenses-$1,346,280CYRevenuesLessExpensesAmt
Total Assets BOY$204,316,428TotalAssetsBOYAmt
Total Assets EOY$219,365,830TotalAssetsEOYAmt
Total Liabilities BOY$28,006,599TotalLiabilitiesBOYAmt
Total Liabilities EOY$29,669,070TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY$176,309,829NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY$189,696,760NetAssetsOrFundBalancesEOYAmt
MissionTB ALLIANCE IS A NOT-FOR-PROFIT ORGANIZATION DEDICATED TO THE DISCOVERY, DEVELOPMENT AND DELIVERY OF BETTER, FASTER-ACTING AND AFFORDABLE TUBERCULOSIS DRUGS THAT ARE AVAILABLE TO THOSE WHO NEED THEM.MissionDesc
Significant New Program SrvcfalseSignificantNewProgramSrvcInd
Significant ChangefalseSignificantChangeInd
Expense$40,409,317ExpenseAmt
Grant$0GrantAmt
Revenue$0RevenueAmt
DescRESEARCH AND DEVELOPMENT - TB ALLIANCE IS A NOT-FOR-PROFIT PRODUCT DEVELOPMENT PARTNERSHIP (PDP), UNIQUELY POSITIONED TO LEVERAGE A GLOBAL NETWORK OF PUBLIC AND PRIVATE PARTNERS TO MOST EFFICIENTLY ADVANCE TB DRUG DEVELOPMENT. A PDP BUILDS PARTNERSHIPS BETWEEN THE PUBLIC, PRIVATE, ACADEMIC, AND PHILANTHROPIC SECTORS TO DRIVE THE DEVELOPMENT OF NEW PRODUCTS FOR UNDERSERVED MARKETS. PDPS RETAIN DIRECT MANAGEMENT OVERSIGHT OF THEIR PROJECTS, THOUGH MUCH OF THE LABORATORY AND CLINICAL WORK IS DONE THROUGH EXTERNAL RESEARCH FACILITIES AND CONTRACTORS. WE COMBINE THE RESEARCH AND DEVELOPMENT EXPERTISE OF OUR STAFF WITH THE SKILLS AND RESOURCES OF OUR PARTNERS TO HARNESS THE MOST PROMISING SCIENCE WHEREVER IT MAY EXIST AROUND THE WORLD. THIS MODEL MINIMIZES COSTS, INCLUDING OVERHEAD AND INVESTMENTS IN INFRASTRUCTURE, WHILE OPTIMIZING SCIENTIFIC CAPABILITY TO SPEED NEW TB DRUG DEVELOPMENT. OUR BUSINESS MODEL AND DIVERSE PARTNERSHIPS ALLOW TB ALLIANCE TO LEVERAGE ADDITIONAL PARTNER SERVICES FOR EVERY DOLLAR INVESTED IN ITS PROGRAMS. NC-009 - NC-009 IS A PAN-PHASE 2 CLINICAL TRIAL INCORPORATING ELEMENTS OF PHASE 2A, B, AND C TO EVALUATE THE SAFETY AND EFFICACY OF A COMBINATION OF A NEW EXPERIMENTAL COMPOUND, SORFEQUILINE (FORMERLY KNOWN AS TBAJ-876), WITH PRETOMANID AND LINEZOLID, COMPONENTS OF TB ALLIANCE'S BPAL REGIMEN. THIS REGIMEN HAS THE POTENTIAL TO SHORTEN AND IMPROVE TREATMENT FOR BOTH DRUG-SENSITIVE AND DRUG-RESISTANT FORMS OF TB. RESULTS FROM PRECLINICAL AND PHASE 1 STUDIES WERE PRESENTED AT THE 2023 UNION CONFERENCE ON LUNG HEALTH AND SHOWED THAT THE NEW COMPOUND, SORFEQUILINE, WHEN COMPARED WITH BEDAQUILINE (A TB MEDICINE IN THE SAME DRUG CLASS), ELIMINATED TB BACTERIA FASTER AND HAD A POTENTIALLY SAFER PROFILE. NC-009 TESTED DIFFERENT DOSES OF SORFEQUILINE IN COMBINATION WITH PRETOMANID AND LINEZOLID AGAINST THE CURRENT STANDARD OF CARE FOR DRUG-SENSITIVE TB - ISONIAZID, RIFAMPICIN, PYRAZINAMIDE, AND ETHEMBUTOL (HRZE). ANOTHER ARM OF THE TRIAL ALSO TESTED PRETOMANID AND LINEZOLID IN COMBINATION WITH BEDAQUILINE (BPAL), A REGIMEN NOW RECOMMENDED BY THE WORLD HEALTH ORGANIZATION TO TREAT SOME FORMS OF DR-TB, AGAINST DRUG-SENSITIVE TB. THE STUDY ENROLLED APPROXIMATELY 300 PARTICIPANTS WITH DRUG-SENSITIVE TB AT 21 CLINICAL TRIAL SITES IN FIVE COUNTRIES: GEORGIA, PHILIPPINES, SOUTH AFRICA, TANZANIA, AND UGANDA. THE RESULTS OF THE NC-009 CLINICAL TRIAL WERE PRESENTED AT THE 2025 UNION WORLD CONFERENCE ON LUNG HEALTH IN COPENHAGEN. THE RESULTS OF THE TRIAL SHOWED THAT, OVERALL, SORFEQUILINE HAD GREATER ACTIVITY THAN BEDAQUILINE. THE 100 MG SPAL REGIMEN HAD GREATER ACTIVITY AGAINST TB THAN THE STANDARD OF CARE HRZE (ISONIAZID, RIFAMPIN, PYRAZINAMIDE, AND ETHAMBUTOL), INDICATING THE POTENTIAL TO SHORTEN TREATMENT TIME FOR ACTIVE TB. IN ADDITION, THE SPAL REGIMEN HAD A COMPARABLE SAFETY PROFILE TO THE STANDARD OF CARE FOR PEOPLE WITH DRUG-SENSITIVE TB (DS-TB). Q203 - TELACEBEC (Q203) IS A FIRST IN-CLASS DRUG CANDIDATE AGAINST MYCOBACTERIUM TUBERCULOSIS INFECTION. Q203 TARGETS CYTOCHROME BC1 COMPLEX AND SHOWS POTENT ACTIVITY AGAINST MULTIDRUG-RESISTANT TUBERCULOSIS (MDR-TB). Q203 HAS ALSO BEEN FOUND EFFECTIVE AGAINST BURULI ULCER (MYCOBACTERIUM ULCERANS), A CHRONIC, NECROTIZING DISEASE THAT AFFECTS SKIN AND SOMETIMES BONE AND CAN LEAD TO PERMANENT DEFORMITY AND LONG-TERM DISABILITY, AND LEPROSY (MYCOBACTERIUM LEPRAE). IN 2023, TB ALLIANCE IN-LICENSED Q203 FROM QURIENT, A CLINICAL-STAGE BIOTECHNOLOGY COMPANY BASED IN SOUTH KOREA. IN JULY 2024, A PHASE 2 PROOF-OF-CONCEPT STUDY WAS INITIATED TO EXPLORE THE USE OF TELACEBEC (Q203) TO TREAT BURULI ULCER. IF SUCCESSFUL, A SINGLE DRUG COULD CUT TREATMENT DURATION BY MORE THAN HALF. IN PARTNERSHIP WITH TB ALLIANCE AND WITH SUPPORT FROM QURIENT CO. LTD, PROFESSOR DANIEL O'BRIEN - A PROMINENT CLINICIAN-RESEARCHER AND EXPERT IN BURULI ULCER - IS LEADING THE STUDY AT BARWON HEALTH AND THE ROYAL MELBOURNE HOSPITAL IN AUSTRALIA. THE FIRST COHORT FOR THE TRIAL ENROLLED APPROXIMATELY 40 ADULT PATIENTS WITH BURULI ULCER WHO WILL RECEIVE 28 DAYS OF TELACEBEC (300MG) ONCE DAILY, FOLLOWED BY A YEAR OF OBSERVATION. PRELIMINARY RESULTS WERE REPORTED IN 2025 AND WERE POSITIVE. A SECOND COHORT OF PARTICIPANTS, ABOUT 80 ADDITIONAL PARTICIPANTS, WERE ENROLLED BY THE BEGINNING OF 2026 AND THE TRIAL IS CURRENTLY ONGOING. TBAJ-587 - THIS NEXT-GENERATION DIARYLQUINOLINE PROJECT HAS SHOWN POTENTIAL TO MAINTAIN BEDAQUILINE'S IMPRESSIVE ANTI-TB ACTIVITIES WHILE RETAINING ADDITIONAL IMPROVED PROPERTIES. TBAJ-587 IS BEING STUDIED THROUGH THE INNOVATIVE HEALTH INITIATIVE'S ERA4TB PROJECT AND, IN 2024, TBAJ-587 COMPLETED A PHASE I TRIAL DEMONSTRATING POSITIVE RESULTS. RESULTS PUBLICATIONS ARE UNDERWAY. AS OF AUGUST 2026, THE PHASE 2 TRIAL, NAMED SYNERGY, WILL SOON BEGIN ENROLLMENT IN SOUTH AFRICA UNDER THE INNOVATIVE HEALTH INITIATIVE'S UNITE4TB PROGRAM.Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

FieldValueIRS element (for citing)
Expense$5,645,557ExpenseAmt
Grant$299,510GrantAmt
Revenue$0RevenueAmt
DescPUBLIC AFFAIRS AND POLICY - TB ALLIANCE MAINTAINS CRITICAL ALLIANCES WITH PUBLIC AND PRIVATE ORGANIZATIONS TO RAISE AWARENESS ABOUT TUBERCULOSIS ("TB") AND ADVOCATE FOR PUBLIC AND PRIVATE INVOLVEMENT IN RESEARCH FOR THE PUBLIC GOOD. SPECIFICALLY, TB ALLIANCE NEGOTIATES TERMS THAT SUPPORT THE DEVELOPMENT AND ACCESS OF NEW AFFORDABLE ANTI-TB DRUGS EQUITABLY FOR THOSE AREAS MOST IN NEED WHILE ENCOURAGING THE PRIVATE SECTOR ON THE DEVELOPMENT OF THESE MEDICINES. TB ALLIANCE CONTINUES TO PURSUE AN EXPLICIT COMMITMENT TO OUR "AAA MANDATE" - THAT ALL NEW PRODUCTS WILL BE ADOPTED, AVAILABLE AND AFFORDABLE TO THOSE WITH TB.Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

FieldValueIRS element (for citing)
Expense$811,284ExpenseAmt
Grant$0GrantAmt
Revenue$0RevenueAmt
DescBUSINESS DEVELOPMENT - TB ALLIANCE NEGOTIATES, IMPLEMENTS AND MANAGES AGREEMENTS WITH PUBLIC AND PRIVATE ORGANIZATIONS WORLDWIDE AND DOES SO BY ADHERING TO SOUND BUSINESS PRACTICES WHILE ENSURING THE PUBLIC GOOD. SPECIFICALLY, TB ALLIANCE NEGOTIATES TERMS THAT SUPPORT THE DEVELOPMENT AND ACCESS OF NEW AFFORDABLE ANTI-TB DRUGS EQUITABLY TO THOSE AREAS MOST IN NEED WHILE ENCOURAGING THE PRIVATE SECTOR TO HELP DEVELOP NEW MEDICINES FOR TB INDICATIONS.Desc
FieldValueIRS element (for citing)
Total Program Service Expenses$46,866,158TotalProgramServiceExpensesAmt
Described In Section501c3Yes (true)DescribedInSection501c3Ind
Schedule B RequiredYes (true)ScheduleBRequiredInd
Political Campaign ActyfalsePoliticalCampaignActyInd
Lobbying ActivitiesfalseLobbyingActivitiesInd
Subject To Proxy TaxfalseSubjectToProxyTaxInd
Donor Advised FundfalseDonorAdvisedFundInd
Conservation EasementsfalseConservationEasementsInd
Collections Of ArtfalseCollectionsOfArtInd
Credit CounselingfalseCreditCounselingInd
Donor Rstr Or Quasi EndowmentsfalseDonorRstrOrQuasiEndowmentsInd
Report Land Building EquipmentYes (true)ReportLandBuildingEquipmentInd
Report Investments Other SecYes (true)ReportInvestmentsOtherSecInd
Report Program Related InvstfalseReportProgramRelatedInvstInd
Report Other AssetsYes (true)ReportOtherAssetsInd
Report Other LiabilitiesYes (true)ReportOtherLiabilitiesInd
Include FIN48 FootnoteYes (true)IncludeFIN48FootnoteInd
Independent Audit Fincl StmtYes (true)IndependentAuditFinclStmtInd
Consolidated Audit Fincl StmtfalseConsolidatedAuditFinclStmtInd
School OperatingfalseSchoolOperatingInd
Foreign OfficeYes (true)ForeignOfficeInd
Foreign ActivitiesYes (true)ForeignActivitiesInd
More Than5000 K To OrgYes (true)MoreThan5000KToOrgInd
More Than5000 K To IndividualsfalseMoreThan5000KToIndividualsInd
Professional FundraisingfalseProfessionalFundraisingInd
Fundraising ActivitiesfalseFundraisingActivitiesInd
Gaming ActivitiesfalseGamingActivitiesInd
Operate HospitalfalseOperateHospitalInd
Grants To OrganizationsfalseGrantsToOrganizationsInd
Grants To IndividualsfalseGrantsToIndividualsInd
Schedule J RequiredYes (true)ScheduleJRequiredInd
Tax Exempt BondsfalseTaxExemptBondsInd
Escrow AccountfalseEscrowAccountInd
On Behalf Of IssuerfalseOnBehalfOfIssuerInd
Engaged In Excess Benefit TransfalseEngagedInExcessBenefitTransInd
PY Excess Benefit TransfalsePYExcessBenefitTransInd
Loan OutstandingfalseLoanOutstandingInd
Grant To Related PersonfalseGrantToRelatedPersonInd
Business Rln With Org MemfalseBusinessRlnWithOrgMemInd
Business Rln With Fam MemfalseBusinessRlnWithFamMemInd
Business Rln With35 Ctrl EntfalseBusinessRlnWith35CtrlEntInd
Deductible Non Cash ContrifalseDeductibleNonCashContriInd
Deductible Art ContributionfalseDeductibleArtContributionInd
Terminate OperationsfalseTerminateOperationsInd
Partial LiquidationfalsePartialLiquidationInd
Disregarded EntityfalseDisregardedEntityInd
Related EntityfalseRelatedEntityInd
Related Organization Ctrl EntfalseRelatedOrganizationCtrlEntInd
Transaction With Control EntfalseTransactionWithControlEntInd
Trnsfr Exmpt Non Chrtbl Rltd OrgfalseTrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted PrtshpfalseActivitiesConductedPrtshpInd
Schedule O RequiredYes (true)ScheduleORequiredInd
IRP Document50IRPDocumentCnt
IRP Document W2 G0IRPDocumentW2GCnt
Backup Wthld ComplianceYes (true)BackupWthldComplianceInd
Employee49EmployeeCnt
Employment Tax Returns FiledYes (true)EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over LimitfalseUnrelatedBusIncmOverLimitInd
Foreign Financial AccountfalseForeignFinancialAccountInd
Prohibited Tax Shelter TransfalseProhibitedTaxShelterTransInd
Taxable Party NotificationfalseTaxablePartyNotificationInd
Nondeductible ContributionsfalseNondeductibleContributionsInd
Quid Pro Quo ContributionsfalseQuidProQuoContributionsInd
Form8282 Property Disposed OffalseForm8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft CntrctfalseRcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft CntrctfalsePayPremiumsPrsnlBnftCntrctInd
Indoor Tanning ServicesfalseIndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht PymtfalseSubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst IncfalseSubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VIYes (X)InfoInScheduleOPartVIInd
Governing Body Voting Members11GoverningBodyVotingMembersCnt
Independent Voting Member10IndependentVotingMemberCnt
Family Or Business RlnfalseFamilyOrBusinessRlnInd
Delegation Of Mgmt DutiesfalseDelegationOfMgmtDutiesInd
Change To Org DocumentsfalseChangeToOrgDocumentsInd
Material Diversion Or MisusefalseMaterialDiversionOrMisuseInd
Members Or StockholdersfalseMembersOrStockholdersInd
Election Of Board MembersfalseElectionOfBoardMembersInd
Decisions Subject To ApprovafalseDecisionsSubjectToApprovaInd
Minutes Of Governing BodyYes (true)MinutesOfGoverningBodyInd
Minutes Of CommitteesYes (true)MinutesOfCommitteesInd
Officer Mailing AddressfalseOfficerMailingAddressInd
Local ChaptersfalseLocalChaptersInd
Policies Reference ChaptersfalsePoliciesReferenceChaptersInd
Form990 Provided To Gvrn BodyYes (true)Form990ProvidedToGvrnBodyInd
Conflict Of Interest PolicyYes (true)ConflictOfInterestPolicyInd
Annual Disclosure Covered PrsnYes (true)AnnualDisclosureCoveredPrsnInd
Regular Monitoring EnfrcYes (true)RegularMonitoringEnfrcInd
Whistleblower PolicyYes (true)WhistleblowerPolicyInd
Document Retention PolicyYes (true)DocumentRetentionPolicyInd
Compensation Process CEOYes (true)CompensationProcessCEOInd
Compensation Process OtherYes (true)CompensationProcessOtherInd
Investment In Joint VenturefalseInvestmentInJointVentureInd
Written Policy Or ProcedurefalseWrittenPolicyOrProcedureInd
States Where Copy Of Return Is FldNYStatesWhereCopyOfReturnIsFldCd
Own WebsiteYes (X)OwnWebsiteInd
Upon RequestYes (X)UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1ANGELA VANDERPLOEGBusinessNameLine1Txt
FieldValueIRS element (for citing)
Phone2122277540PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line180 PINE STREET 20TH FLOORAddressLine1Txt
CityNEW YORKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP10005ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (22 entries)

TitleTitleTxtAverage Hours Per WeekAverageHoursPerWeekRtAverage Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRtIndividual Trustee Or DirectorIndividualTrusteeOrDirectorIndOfficerOfficerIndReportable Comp From OrgReportableCompFromOrgAmtReportable Comp From Rltd OrgReportableCompFromRltdOrgAmtOther CompensationOtherCompensationAmtKey EmployeeKeyEmployeeIndHighest Compensated EmployeeHighestCompensatedEmployeeInd
DAVID NORTON
CHAIR3.00.0Yes (X)Yes (X)$0$0$0
ERIC GOOSBY
VICE-CHAIR3.00.0Yes (X)Yes (X)$0$0$0
MELVIN SPIGELMAN
PRESIDENT/CEO45.00.0Yes (X)Yes (X)$979,462$0$115,515
AKSHAY VAISHNAW
DIRECTOR3.00.0Yes (X)$0$0$0
ANN TAYLOR
DIRECTOR3.00.0Yes (X)$0$0$0
KIM SCHWARTZ
DIRECTOR3.00.0Yes (X)$0$0$0
MITCHELL WARREN
DIRECTOR3.00.0Yes (X)$0$0$0
RASHA HIBRI
DIRECTOR3.00.0Yes (X)$0$0$0
RATAN WATAL
DIRECTOR3.00.0Yes (X)$0$0$0
SRISHTI GUPTA
DIRECTOR3.00.0Yes (X)$0$0$0
SUNDAR KODIYALAM
DIRECTOR3.00.0Yes (X)$0$0$0
ANGELA VANDERPLOEG
TREASURER/CFO45.00.0Yes (X)$442,294$0$108,145
COLLEEN PERO
SECRETARY/CAO45.00.0Yes (X)$489,385$0$73,926
EUGENE SUN
SR. VP, RESEARCH & DEVELOPMENT45.00.0$604,382$0$98,971Yes (X)
MARIA BEUMONT
VP, CHIEF MEDICAL OFFICER45.00.0$514,534$0$86,878Yes (X)
NADER FOTOUHI
SR. VP, CHIEF SCIENTIFIC OFFICER45.00.0$586,613$0$121,980Yes (X)
PIETRO O TURILLI
SR. VP, EXTERNAL AFFAIRS (THRU 11/30/25)45.00.0$368,685$0$94,564Yes (X)
KATHLEEN SCHOSTACK
SR. VP, PROGRAM & ALLIANCE MANAGEMENT (THRU 08/31/25)45.00.0$379,734$0$63,868Yes (X)
RAJNEESH TANEJA
VP, PHARMACEUTICAL PRODUCT DEVELOPMENT45.00.0$392,025$0$84,435Yes (X)
ROBERT LORETTE
SR. VP, BUSINESS DEVELOPMENT45.00.0$467,971$0$90,517Yes (X)
SALAH FORAIDA
SR. DIRECTOR, MEDICAL AFFAIRS45.00.0$446,439$0$54,163Yes (X)
SANDEEP JUNEJA
SR. VP, MARKET ACCESS45.00.0$435,088$0$107,467Yes (X)
FieldValueIRS element (for citing)
Total Reportable Comp From Org$6,106,612TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org$0TotReportableCompRltdOrgAmt
Total Other Compensation$1,100,429TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K42IndivRcvdGreaterThan100KCnt
Former Ofcr Employees ListedfalseFormerOfcrEmployeesListedInd
Total Comp Greater Than150 KYes (true)TotalCompGreaterThan150KInd
Compensation From Other SrcsfalseCompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1TxtCityContractorAddress/USAddress/CityNmState AbbreviationContractorAddress/USAddress/StateAbbreviationCdZIPContractorAddress/USAddress/ZIPCdServicesServicesDescCompensationCompensationAmtAddress Line1ContractorAddress/ForeignAddress/AddressLine1TxtCityContractorAddress/ForeignAddress/CityNmCountryContractorAddress/ForeignAddress/CountryCd
PPD DEVELOPMENT LP
26361 NETWORK PLACECHICAGOIL60673GLOBAL CRO$3,821,476
WUXI APPTEC (HONGKONG) LIMITED
INTEGRATED R&D SERVICES$3,048,268UNIT C 20/F NO 998 CANTON RDKOWLOONHK
RTI INTERNATIONAL
PO BOX 900002RALEIGHNC27675INTEGRATED R&D SERVICES$1,247,412
GLAXOSMITHKLINE INVESTIGACIN Y DESARROLLO SL
EXTERNAL MINI PORTFOLIOS$1,200,00028760 TRES CANTOSMADRIDSP
JOHNS HOPKINS UNIVERSITY CENTRAL
12529 COLLECTIONS CENTER DRIVECHICAGOIL60693INTEGRATED R&D SERVICES$1,184,064
FieldValueIRS element (for citing)
Cntrct Rcvd Greater Than100 K70CntrctRcvdGreaterThan100KCnt
Government Grants$24,601,930GovernmentGrantsAmt
All Other Contributions$17,296,471AllOtherContributionsAmt
Total Contributions$41,898,401TotalContributionsAmt

Total Oth Program Service Rev TotalOthProgramServiceRevGrp

FieldValueIRS element (for citing)
Total Revenue Column$0TotalRevenueColumnAmt
Related Or Exempt Func Income$0RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue$0UnrelatedBusinessRevenueAmt
Exclusion$0ExclusionAmt
FieldValueIRS element (for citing)
Total Program Service Revenue$0TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

FieldValueIRS element (for citing)
Total Revenue Column$3,189,504TotalRevenueColumnAmt
Related Or Exempt Func Income$0RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue$0UnrelatedBusinessRevenueAmt
Exclusion$3,189,504ExclusionAmt

Royalties Revenue RoyaltiesRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$572,608TotalRevenueColumnAmt
Related Or Exempt Func Income$0RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue$0UnrelatedBusinessRevenueAmt
Exclusion$572,608ExclusionAmt

Rental Income Or Loss RentalIncomeOrLossGrp

FieldValueIRS element (for citing)
Real$0RealAmt
Personal$0PersonalAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

FieldValueIRS element (for citing)
Securities$29,110,972SecuritiesAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

FieldValueIRS element (for citing)
Securities$24,354,159SecuritiesAmt

Gain Or Loss GainOrLossGrp

FieldValueIRS element (for citing)
Securities$4,756,813SecuritiesAmt
Other$0OtherAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

FieldValueIRS element (for citing)
Total Revenue Column$4,756,813TotalRevenueColumnAmt
Related Or Exempt Func Income$0RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue$0UnrelatedBusinessRevenueAmt
Exclusion$4,756,813ExclusionAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

FieldValueIRS element (for citing)
Total Revenue Column$0TotalRevenueColumnAmt

Other Revenue Misc OtherRevenueMiscGrp

FieldValueIRS element (for citing)
DescMISCELLANEOUS INCOMEDesc
Business900099BusinessCd
Total Revenue Column$2,127,730TotalRevenueColumnAmt
Related Or Exempt Func Income$0RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue$0UnrelatedBusinessRevenueAmt
Exclusion$2,127,730ExclusionAmt

Miscellaneous Revenue MiscellaneousRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$0TotalRevenueColumnAmt
Related Or Exempt Func Income$0RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue$0UnrelatedBusinessRevenueAmt
Exclusion$0ExclusionAmt
FieldValueIRS element (for citing)
Other Revenue Total$2,127,730OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$52,545,056TotalRevenueColumnAmt
Related Or Exempt Func Income$0RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue$0UnrelatedBusinessRevenueAmt
Exclusion$10,646,655ExclusionAmt
FieldValueIRS element (for citing)
Info In Schedule O Part IXYes (X)InfoInScheduleOPartIXInd

Foreign Grants ForeignGrantsGrp

FieldValueIRS element (for citing)
Total$299,510TotalAmt
Program Services$299,510ProgramServicesAmt

Benefits To Members BenefitsToMembersGrp

FieldValueIRS element (for citing)
Total$0TotalAmt
Program Services$0ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

FieldValueIRS element (for citing)
Total$4,698,570TotalAmt
Program Services$3,043,991ProgramServicesAmt
Management And General$1,121,846ManagementAndGeneralAmt
Fundraising$532,733FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

FieldValueIRS element (for citing)
Total$10,108,129TotalAmt
Program Services$8,211,807ProgramServicesAmt
Management And General$1,725,071ManagementAndGeneralAmt
Fundraising$171,251FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

FieldValueIRS element (for citing)
Total$927,578TotalAmt
Program Services$760,445ProgramServicesAmt
Management And General$151,498ManagementAndGeneralAmt
Fundraising$15,635FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

FieldValueIRS element (for citing)
Total$1,364,772TotalAmt
Program Services$1,117,537ProgramServicesAmt
Management And General$238,435ManagementAndGeneralAmt
Fundraising$8,800FundraisingAmt

Payroll Taxes PayrollTaxesGrp

FieldValueIRS element (for citing)
Total$779,557TotalAmt
Program Services$598,124ProgramServicesAmt
Management And General$148,069ManagementAndGeneralAmt
Fundraising$33,364FundraisingAmt

Fees For Services Legal FeesForServicesLegalGrp

FieldValueIRS element (for citing)
Total$787,905TotalAmt
Program Services$668,194ProgramServicesAmt
Management And General$119,711ManagementAndGeneralAmt
Fundraising$0FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

FieldValueIRS element (for citing)
Total$117,674TotalAmt
Program Services$15,600ProgramServicesAmt
Management And General$102,074ManagementAndGeneralAmt
Fundraising$0FundraisingAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

FieldValueIRS element (for citing)
Total$427,243TotalAmt
Program Services$0ProgramServicesAmt
Management And General$427,243ManagementAndGeneralAmt
Fundraising$0FundraisingAmt

Fees For Services Other FeesForServicesOtherGrp

FieldValueIRS element (for citing)
Total$6,327,742TotalAmt
Program Services$5,823,234ProgramServicesAmt
Management And General$294,800ManagementAndGeneralAmt
Fundraising$209,708FundraisingAmt

Office Expenses OfficeExpensesGrp

FieldValueIRS element (for citing)
Total$247,274TotalAmt
Program Services$23,193ProgramServicesAmt
Management And General$223,901ManagementAndGeneralAmt
Fundraising$180FundraisingAmt

Information Technology InformationTechnologyGrp

FieldValueIRS element (for citing)
Total$1,151,825TotalAmt
Program Services$481,345ProgramServicesAmt
Management And General$645,239ManagementAndGeneralAmt
Fundraising$25,241FundraisingAmt

Occupancy OccupancyGrp

FieldValueIRS element (for citing)
Total$1,368,458TotalAmt
Program Services$1,026,135ProgramServicesAmt
Management And General$293,931ManagementAndGeneralAmt
Fundraising$48,392FundraisingAmt

Travel TravelGrp

FieldValueIRS element (for citing)
Total$999,138TotalAmt
Program Services$805,109ProgramServicesAmt
Management And General$158,536ManagementAndGeneralAmt
Fundraising$35,493FundraisingAmt

Conferences Meetings ConferencesMeetingsGrp

FieldValueIRS element (for citing)
Total$120,244TotalAmt
Program Services$110,542ProgramServicesAmt
Management And General$8,868ManagementAndGeneralAmt
Fundraising$834FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

FieldValueIRS element (for citing)
Total$276,848TotalAmt
Program Services$202,937ProgramServicesAmt
Management And General$64,079ManagementAndGeneralAmt
Fundraising$9,832FundraisingAmt

Insurance InsuranceGrp

FieldValueIRS element (for citing)
Total$201,787TotalAmt
Program Services$42,014ProgramServicesAmt
Management And General$159,773ManagementAndGeneralAmt
Fundraising$0FundraisingAmt

Other Expenses OtherExpensesGrp (2 entries)

DescDescTotalTotalAmtProgram ServicesProgramServicesAmtManagement And GeneralManagementAndGeneralAmtFundraisingFundraisingAmt
R&D PROJECT EXPENSES$23,586,534$23,586,534$0$0
DUES AND SUBSCRIPTIONS$100,548$49,907$27,725$22,916

All Other Expenses AllOtherExpensesGrp

FieldValueIRS element (for citing)
Total$0TotalAmt
Program Services$0ProgramServicesAmt
Management And General$0ManagementAndGeneralAmt
Fundraising$0FundraisingAmt

Total Functional Expenses TotalFunctionalExpensesGrp

FieldValueIRS element (for citing)
Total$53,891,336TotalAmt
Program Services$46,866,158ProgramServicesAmt
Management And General$5,910,799ManagementAndGeneralAmt
Fundraising$1,114,379FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

FieldValueIRS element (for citing)
BOY$34,377,400BOYAmt
EOY$20,839,065EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

FieldValueIRS element (for citing)
BOY$6,609,856BOYAmt
EOY$5,970,313EOYAmt

Accounts Receivable AccountsReceivableGrp

FieldValueIRS element (for citing)
BOY$1,081,288BOYAmt
EOY$1,230,556EOYAmt

Receivables From Officers Etc ReceivablesFromOfficersEtcGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Rcvbl From Disqualified Prsn RcvblFromDisqualifiedPrsnGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

FieldValueIRS element (for citing)
BOY$1,196,922BOYAmt
EOY$1,259,801EOYAmt
FieldValueIRS element (for citing)
Land Bldg Equip Cost Or Other Bss$1,723,113LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec$673,845LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

FieldValueIRS element (for citing)
BOY$1,320,475BOYAmt
EOY$1,049,268EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

FieldValueIRS element (for citing)
BOY$80,443,114BOYAmt
EOY$88,304,886EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

FieldValueIRS element (for citing)
BOY$64,373,689BOYAmt
EOY$86,595,017EOYAmt

Investments Program Related InvestmentsProgramRelatedGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt

Other Assets Total OtherAssetsTotalGrp

FieldValueIRS element (for citing)
BOY$14,913,684BOYAmt
EOY$14,116,924EOYAmt

Total Assets TotalAssetsGrp

FieldValueIRS element (for citing)
BOY$204,316,428BOYAmt
EOY$219,365,830EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

FieldValueIRS element (for citing)
BOY$8,739,913BOYAmt
EOY$8,417,258EOYAmt

Deferred Revenue DeferredRevenueGrp

FieldValueIRS element (for citing)
BOY$2,621,045BOYAmt
EOY$5,500,744EOYAmt

Loans From Officers Directors LoansFromOfficersDirectorsGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Other Liabilities OtherLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$16,645,641BOYAmt
EOY$15,751,068EOYAmt

Total Liabilities TotalLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$28,006,599BOYAmt
EOY$29,669,070EOYAmt
FieldValueIRS element (for citing)
Organization Follows FASB117Yes (X)OrganizationFollowsFASB117Ind

No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp

FieldValueIRS element (for citing)
BOY$176,309,829BOYAmt
EOY$189,696,760EOYAmt

Donor Restriction Net Assets DonorRestrictionNetAssetsGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$176,309,829BOYAmt
EOY$189,696,760EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$204,316,428BOYAmt
EOY$219,365,830EOYAmt
FieldValueIRS element (for citing)
Info In Schedule O Part XIYes (X)InfoInScheduleOPartXIInd
Reconcilation Revenue Expnss-$1,346,280ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst$14,777,632NetUnrlzdGainsLossesInvstAmt
Other Changes In Net Assets-$44,421OtherChangesInNetAssetsAmt
Method Of Accounting AccrualYes (X)MethodOfAccountingAccrualInd
Accountant Compile Or ReviewfalseAccountantCompileOrReviewInd
FS AuditedYes (true)FSAuditedInd
Audit CommitteeYes (true)AuditCommitteeInd
Federal Grant Audit RequiredYes (true)FederalGrantAuditRequiredInd
Federal Grant Audit PerformedYes (true)FederalGrantAuditPerformedInd

Schedule A IRS990ScheduleA

FieldValueIRS element (for citing)
Public Organization170Yes (X)PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$58,183,286CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$52,646,326CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$49,796,816CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$52,737,212CurrentTaxYearMinus1YearAmt
Current Tax Year$41,898,401CurrentTaxYearAmt
Total$255,262,041TotalAmt

Tax Rev Levied Orgnztnl Bnft170 TaxRevLeviedOrgnztnlBnft170Grp

FieldValueIRS element (for citing)
Current Tax Year$0CurrentTaxYearAmt
Total$0TotalAmt

Govt Furn Srvc Fclts Vl170 GovtFurnSrvcFcltsVl170Grp

FieldValueIRS element (for citing)
Current Tax Year$0CurrentTaxYearAmt
Total$0TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$58,183,286CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$52,646,326CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$49,796,816CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$52,737,212CurrentTaxYearMinus1YearAmt
Current Tax Year$41,898,401CurrentTaxYearAmt
Total$255,262,041TotalAmt
FieldValueIRS element (for citing)
Substantial Contributors Tot$82,192,682SubstantialContributorsTotAmt
Public Support Total170$173,069,358PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$77,877CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$2,686,767CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$8,339,176CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$6,406,586CurrentTaxYearMinus1YearAmt
Current Tax Year$3,762,112CurrentTaxYearAmt
Total$21,272,518TotalAmt

Unrelated Business Net Incm170 UnrelatedBusinessNetIncm170Grp

FieldValueIRS element (for citing)
Current Tax Year$0CurrentTaxYearAmt
Total$0TotalAmt

Other Income170 OtherIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$392,216CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$901,316CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$1,981,851CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$932,353CurrentTaxYearMinus1YearAmt
Current Tax Year$2,127,730CurrentTaxYearAmt
Total$6,335,466TotalAmt
FieldValueIRS element (for citing)
Total Support$282,870,025TotalSupportAmt
Gross Receipts Rltd Activities$0GrossReceiptsRltdActivitiesAmt
Public Support CY1700.61183PublicSupportCY170Pct
Public Support PY1700.62836PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170Yes (X)ThirtyThrPctSuprtTestsCY170Ind

Form990 Schedule A Part VI Form990ScheduleAPartVIGrp

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE A, PART II, LINE 10 OTHER INCOMEFormAndLineReferenceDesc
ExplanationDESCRIPTION - , COLUMN A - 392216.0, COLUMN B - 901316.0, COLUMN C - 1981851.0, COLUMN D - 932353.0, COLUMN E - 2127730.0, COLUMN F - 6335466.0;ExplanationTxt

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

FieldValueIRS element (for citing)
ContributorRESTRICTEDContributorNum

Contributor Business Name ContributorBusinessName

FieldValueIRS element (for citing)
Business Name Line1RESTRICTEDBusinessNameLine1

Contributor US Address ContributorUSAddress

FieldValueIRS element (for citing)
Address Line1RESTRICTEDAddressLine1
Address Line2RESTRICTEDAddressLine2
CityRESTRICTEDCity
StateRESTRICTEDState
ZIP CodeRESTRICTEDZIPCode
FieldValueIRS element (for citing)
Total ContributionsRESTRICTEDTotalContributionsAmt

Schedule D IRS990ScheduleD

Leasehold Improvements LeaseholdImprovementsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$636,260OtherCostOrOtherBasisAmt
Depreciation$101,369DepreciationAmt
Book Value$534,891BookValueAmt

Equipment EquipmentGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$99,819OtherCostOrOtherBasisAmt
Depreciation$80,965DepreciationAmt
Book Value$18,854BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$987,034OtherCostOrOtherBasisAmt
Depreciation$491,511DepreciationAmt
Book Value$495,523BookValueAmt
FieldValueIRS element (for citing)
Total Book Value Land Buildings$1,049,268TotalBookValueLandBuildingsAmt

Other Securities OtherSecuritiesGrp (3 entries)

DescDescBook ValueBookValueAmtMethod ValuationMethodValuationCd
CLOSELY-HELD EQUITY INTERESTS
FINANCIAL DERIVATIVES
INVESTMENTS IN LIMITED PARTNERSHIP$86,595,017F
FieldValueIRS element (for citing)
Total Book Value Securities$86,595,017TotalBookValueSecuritiesAmt

Other Assets Org OtherAssetsOrgGrp (2 entries)

DescDescBook ValueBookValueAmt
RIGHT-OF-USE ASSETS - OPERATING LEASES$13,971,690
SECURITY DEPOSITS$145,234
FieldValueIRS element (for citing)
Total Book Value Other Assets$14,116,924TotalBookValueOtherAssetsAmt

Other Liabilities Org OtherLiabilitiesOrgGrp (2 entries)

DescDescAmtAmt
FEDERAL INCOME TAXES
OPERATING LEASE LIABILITIES$15,751,068
FieldValueIRS element (for citing)
Total Liability$15,751,068TotalLiabilityAmt
Footnote TextYes (X)FootnoteTextInd
Total Rev Etc Audited Fincl Stmt$66,895,445TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst$14,777,632NetUnrealizedGainsInvstAmt
Other Revenue$0OtherRevenueAmt
Revenue Not Reported$14,777,632RevenueNotReportedAmt
Revenue Subtotal$52,117,813RevenueSubtotalAmt
Investment Expenses Not Incld$427,243InvestmentExpensesNotIncldAmt
Other Revenues Not Included$0OtherRevenuesNotIncludedAmt
Revenue Not Reported Fincl Stmt$427,243RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990$52,545,056TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt$53,464,093TotExpnsEtcAuditedFinclStmtAmt
Other Expenses Included$0OtherExpensesIncludedAmt
Expenses Not Reported$0ExpensesNotReportedAmt
Expenses Subtotal$53,464,093ExpensesSubtotalAmt
Investment Expenses Not Incld2$427,243InvestmentExpensesNotIncld2Amt
Other Expenses Not Included$0OtherExpensesNotIncludedAmt
Expenses Not Rpt Fincl Stmt$427,243ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990$53,891,336TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE D, PART X, LINE 2 FIN 48 (ASC 740) FOOTNOTEFormAndLineReferenceDesc
ExplanationTB ALLIANCE IS SUBJECT TO THE PROVISIONS OF THE FINANCIAL ACCOUNTING STANDARDS BOARD'S (FASB) ACCOUNTING STANDARDS CODIFICATION (ASC 740), INCOME TAXES (ASC 740), AS IT RELATES TO ACCOUNTING AND REPORTING FOR UNCERTAINTY IN INCOME TAXES. TB ALLIANCE DOES NOT BELIEVE IT HAS TAKEN ANY MATERIAL UNCERTAIN TAX POSITIONS AND, DUE TO ITS GENERAL NOT-FOR-PROFIT STATUS, MANAGEMENT BELIEVES ASC 740 HAS NOT HAD, AND IS NOT ANTICIPATED TO HAVE, A MATERIAL IMPACT ON TB ALLIANCE'S FINANCIAL STATEMENTS.ExplanationTxt

Schedule F IRS990ScheduleF

FieldValueIRS element (for citing)
Grant Records MaintainedYes (true)GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (27 entries)

RegionRegionTxtOfficesOfficesCntEmployeeEmployeeCntType Of Activities ConductedTypeOfActivitiesConductedTxtSpecific Services ProvidedSpecificServicesProvidedTxtRegion Total ExpendituresRegionTotalExpendituresAmt
CENTRAL AMERICA AND THE CARIBBEAN01PROGRAM SERVICESCONSULTING SERVICES$8,751
EAST ASIA AND THE PACIFIC00PROGRAM SERVICESR&D RESEARCH$3,784,435
EAST ASIA AND THE PACIFIC013PROGRAM SERVICESCONSULTING SERVICES$1,015,375
EAST ASIA AND THE PACIFIC00PROGRAM SERVICESADMINISTRATIVE EXP.$14,442
EUROPE (INCLUDING ICELAND AND GREENLAND)00PROGRAM SERVICESR&D RESEARCH$4,645,787
EUROPE (INCLUDING ICELAND AND GREENLAND)016PROGRAM SERVICESCONSULTING SERVICES$1,658,247
EUROPE (INCLUDING ICELAND AND GREENLAND)00PROGRAM SERVICESADMINISTRATIVE EXP.$108,002
EUROPE (INCLUDING ICELAND AND GREENLAND)00GRANTMAKING$18,693
MIDDLE EAST AND NORTH AFRICA00PROGRAM SERVICESADMINISTRATIVE EXP.$14,767
NORTH AMERICA (CANADA & MEXICO ONLY)00PROGRAM SERVICESR&D RESEARCH$132,600
NORTH AMERICA (CANADA & MEXICO ONLY)02PROGRAM SERVICESCONSULTING SERVICES$25,163
NORTH AMERICA (CANADA & MEXICO ONLY)00PROGRAM SERVICESADMINISTRATIVE EXP.$17,971
RUSSIA AND NEIGHBORING STATES04PROGRAM SERVICESCONSULTING SERVICES$150,797
RUSSIA AND NEIGHBORING STATES00PROGRAM SERVICESR&D RESEARCH$120,005
RUSSIA AND NEIGHBORING STATES00GRANTMAKING$17,000
RUSSIA AND NEIGHBORING STATES00PROGRAM SERVICESADMINISTRATIVE EXP.$8,544
SOUTH AMERICA05PROGRAM SERVICESCONSULTING SERVICES$111,776
SOUTH AMERICA00PROGRAM SERVICESR&D RESEARCH$24,584
SOUTH AMERICA00PROGRAM SERVICESADMINISTRATIVE EXPENSES$1,409
SOUTH ASIA00PROGRAM SERVICESR&D RESEARCH$1,391,350
SOUTH ASIA015PROGRAM SERVICESCONSULTING SERVICES$360,377
SOUTH ASIA00PROGRAM SERVICESADMINISTRATIVE EXPENSES$4,757
SUB-SAHARAN AFRICA00PROGRAM SERVICESR&D RESEARCH$2,269,752
SUB-SAHARAN AFRICA06PROGRAM SERVICESSALARY EXPENSES$852,242
SUB-SAHARAN AFRICA00GRANTMAKING$263,817
SUB-SAHARAN AFRICA05PROGRAM SERVICESCONSULTING SERVICES$63,499
SUB-SAHARAN AFRICA10PROGRAM SERVICESADMINISTRATIVE EXPENSES$60,235
FieldValueIRS element (for citing)
Subtotal Offices0SubtotalOfficesCnt
Subtotal Employees36SubtotalEmployeesCnt
Continuation Total Office1ContinuationTotalOfficeCnt
Continuation Total Employee31ContinuationTotalEmployeeCnt
Total Office1TotalOfficeCnt
Total Employee67TotalEmployeeCnt
Subtotal Spent$11,740,579SubtotalSpentAmt
Continuation Spent$5,403,798ContinuationSpentAmt
Total Spent$17,144,377TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (3 entries)

RegionRegionTxtPurpose Of GrantPurposeOfGrantTxtCash GrantCashGrantAmtManner Of Cash DisbursementMannerOfCashDisbursementTxt
EUROPE (INCLUDING ICELAND AND GREENLAND)COMMUNITY ENENGAGEMENT$18,693WIRE
RUSSIA AND NEIGHBORING STATESCOMMUNITY ENENGAGEMENT$17,000WIRE
SUB-SAHARAN AFRICACOMMUNITY ENENGAGEMENT$263,817WIRE
FieldValueIRS element (for citing)
Total501c3 Org3Total501c3OrgCnt
Total Other Org0TotalOtherOrgCnt
Transfer To Foreign CorpfalseTransferToForeignCorpInd
Interest In Foreign TrustfalseInterestInForeignTrustInd
Foreign Corp OwnershipfalseForeignCorpOwnershipInd
Passive Foreign Investmest CofalsePassiveForeignInvestmestCoInd
Foreign PartnershipfalseForeignPartnershipInd
Boycott CountriesfalseBoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (3 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
SCHEDULE F, PART I, LINE 2 PROCEDURES FOR MONITORING USE OF GRANT FUNDSTHE GRANTEE IS REQUIRED TO PROVIDE THE ORGANIZATION WITH AN ITEMIZED ACCOUNTING OF EXPENDITURES FOR THE PROJECT AND A REPORT ON THE PROGRESS OF THE PROJECT ON A SCHEDULE SPECIFIED IN THE AGREEMENT. THIS REQUIREMENT IS OUTLINED IN THE SIGNED AGREEMENT BETWEEN BOTH PARTIES.
SCHEDULE F, PART I, LINE 3 METHOD USED TO ACCOUNT FOR EXPENDITURES ON ORG'S FINANCIAL STATEMENTSCENTRAL AMERICA AND THE CARIBBEAN-ACCRUAL; EAST ASIA AND THE PACIFIC-ACCRUAL; EUROPE (INCLUDING ICELAND AND GREENLAND)-ACCRUAL; MIDDLE EAST AND NORTH AFRICA-ACCRUAL; NORTH AMERICA (CANADA & MEXICO ONLY)-ACCRUAL; RUSSIA AND NEIGHBORING STATES-ACCRUAL; SOUTH AMERICA-ACCRUAL; SOUTH ASIA-ACCRUAL; SUB-SAHARAN AFRICA-ACCRUAL
SCHEDULE F, PART II, LINE 1 METHOD USED TO ACCOUNT FOR EXPENDITURES ON ORG'S FINANCIAL STATEMENTSEUROPE (INCLUDING ICELAND AND GREENLAND)-ACCRUAL; RUSSIA AND NEIGHBORING STATES-ACCRUAL; SUB-SAHARAN AFRICA-ACCRUAL

Schedule J IRS990ScheduleJ

FieldValueIRS element (for citing)
Compensation CommitteeYes (X)CompensationCommitteeInd
Independent ConsultantYes (X)IndependentConsultantInd
Form990 Of Other OrganizationsYes (X)Form990OfOtherOrganizationsInd
Compensation SurveyYes (X)CompensationSurveyInd
Board Or Committee ApprovalYes (X)BoardOrCommitteeApprovalInd
Severance PaymentfalseSeverancePaymentInd
Supplemental Nonqual Rtr PlanfalseSupplementalNonqualRtrPlanInd
Equity Based Comp ArrngmfalseEquityBasedCompArrngmInd
Comp Based On Revenue Of Flng OrgfalseCompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related OrgsfalseCompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng OrgfalseCompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd OrgsfalseCompBsdNetEarnsRltdOrgsInd
Any Non Fixed PaymentsYes (true)AnyNonFixedPaymentsInd
Initial Contract ExceptionfalseInitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (12 entries)

TitleTitleTxtBase Compensation Filing OrgBaseCompensationFilingOrgAmtCompensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmtBonus Filing OrganizationBonusFilingOrganizationAmountBonus Related OrganizationsBonusRelatedOrganizationsAmtOther Compensation Filing OrgOtherCompensationFilingOrgAmtOther Compensation Rltd OrgsOtherCompensationRltdOrgsAmtDeferred Compensation Flng OrgDeferredCompensationFlngOrgAmtDeferred Comp Rltd OrgsDeferredCompRltdOrgsAmtNontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmtNontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmtTotal Compensation Filing OrgTotalCompensationFilingOrgAmtTotal Compensation Rltd OrgsTotalCompensationRltdOrgsAmtComp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmtComp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
MELVIN SPIGELMAN
PRESIDENT/CEO$688,096$0$291,366$0$0$0$70,000$0$45,515$0$1,094,977$0$0$0
COLLEEN PERO
SECRETARY/CAO$386,933$0$102,452$0$0$0$48,190$0$25,736$0$563,311$0$0$0
ANGELA VANDERPLOEG
TREASURER/CFO$349,263$0$93,031$0$0$0$44,119$0$64,026$0$550,439$0$0$0
NADER FOTOUHI
SR. VP, CHIEF SCIENTIFIC OFFICER$463,255$0$123,358$0$0$0$58,300$0$63,680$0$708,593$0$0$0
EUGENE SUN
SR. VP, RESEARCH & DEVELOPMENT$478,354$0$126,028$0$0$0$55,091$0$43,880$0$703,353$0$0$0
MARIA BEUMONT
VP, CHIEF MEDICAL OFFICER$423,892$0$90,642$0$0$0$46,500$0$40,378$0$601,412$0$0$0
PIETRO O TURILLI
SR. VP, EXTERNAL AFFAIRS (THRU 11/30/25)$278,491$0$76,959$0$13,235$0$36,663$0$57,901$0$463,249$0$0$0
ROBERT LORETTE
SR. VP, BUSINESS DEVELOPMENT$371,624$0$96,347$0$0$0$45,767$0$44,750$0$558,488$0$0$0
SANDEEP JUNEJA
SR. VP, MARKET ACCESS$343,252$0$91,836$0$0$0$43,552$0$63,915$0$542,555$0$0$0
SALAH FORAIDA
SR. DIRECTOR, MEDICAL AFFAIRS$386,235$0$60,204$0$0$0$44,572$0$9,591$0$500,602$0$0$0
RAJNEESH TANEJA
VP, PHARMACEUTICAL PRODUCT DEVELOPMENT$321,485$0$70,540$0$0$0$39,002$0$45,433$0$476,460$0$0$0
KATHLEEN SCHOSTACK
SR. VP, PROGRAM & ALLIANCE MANAGEMENT (THRU 08/31/25)$220,427$0$152,582$0$6,725$0$37,540$0$26,328$0$443,602$0$0$0

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE J, PART I, LINE 7 NON-FIXED PAYMENTSFormAndLineReferenceDesc
ExplanationVARIABLE COMPENSATION IS PAID TO STAFF MEMBERS BASED ON ANNUAL PERFORMANCE. REFER TO SCHEDULE O RESPONSE TO FORM 990, PART VI, SECTION B, LINES 15 A AND 15B FOR FURTHER DETAILS.ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (9 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
FORM 990, PART III, LINE 4A PROGRAM SERVICE DESCRIPTIONSUTEZOLID - SUTEZOLID IS A PROMISING CLINICAL-STAGE TB DRUG CANDIDATE FROM THE OXAZOLIDINONE CLASS. TB ALLIANCE HAS IMPLEMENTED AN OPEN DEVELOPMENT APPROACH TO ADVANCE THE PHASE 2 TB DRUG CANDIDATE, SUTEZOLID, WHICH COULD BE A COMPONENT OF A NEXT-GENERATION TB REGIMEN. TB ALLIANCE HAS MADE SUTEZOLID AVAILABLE FOR STUDY BY ALL RESEARCHERS WHO COMMIT TO MAKING THEIR RESULTS AVAILABLE TO THE BROADER TB RESEARCH COMMUNITY. THIS NOVEL APPROACH HAS CONTRIBUTED TO THREE CLINICAL TRIALS THAT BEGAN IN 2023. PEERLINC - IN 2024, TB ALLIANCE LAUNCHED A NEW PEER-TO-PEER LEARNING FOR INNOVATIVE CURES (PEERLINC) KNOWLEDGE HUB BASED IN MANILA, WITH FUNDING FROM THE AUSTRALIAN GOVERNMENT THROUGH THE PARTNERSHIPS FOR A HEALTHY REGION INITIATIVE. PEERLINC, OPERATING IN PARTNERSHIP BETWEEN TB ALLIANCE AND THE TROPICAL DISEASE FOUNDATION, INC. (TDF), AND IN CLOSE COLLABORATION WITH THE DEPARTMENT OF HEALTH (DOH), PHILIPPINES, WILL HELP COUNTRIES IMPLEMENT BEST PRACTICES IN THE TREATMENT OF DRUG-RESISTANT TUBERCULOSIS (DR-TB) TO HELP SPEED THE WORLDWIDE PROGRAMMATIC IMPLEMENTATION OF INNOVATIVE, MORE EFFECTIVE TREATMENTS FOR THE DISEASE, STARTING WITH THE WORLD HEALTH ORGANIZATION (WHO)-RECOMMENDED SIX-MONTH, ALL-ORAL BPAL/M REGIMENS, COMPOSED OF THE ANTIBIOTICS BEDAQUILINE (B), PRETOMANID (PA), AND LINEZOLID (L), WITH OR WITHOUT MOXIFLOXACIN (M). PEERLINC WILL PROVIDE PRACTICAL TRAINING AND TECHNICAL ASSISTANCE TO COUNTRIES TO SUPPORT THIS OBJECTIVE, VIA EXPERTS FROM THE PHILIPPINES AND THE DEPARTMENT OF HEALTH, INCLUDING LUNG CENTER OF THE PHILIPPINES AND THE NATIONAL TB REFERENCE LABORATORY (NTRL). THE PHILIPPINES HAS SUCCESSFULLY AND RAPIDLY DEPLOYED NEW TREATMENTS THROUGH PARTICIPATION IN TB ALLIANCE'S LEVERAGING INNOVATION FOR FASTER TB TREATMENT (LIFT-TB) INITIATIVE. IN 2024 ALONE, THE PEERLINC KNOWLEDGE HUB COMPLETED TRAININGS WITH LEADERS, EXPERTS, AND STAFF FROM NATIONAL TB PROGRAMS IN SEVEN COUNTRIES: PERU, DRC, NIGERIA, BRAZIL, CAMBODIA, TANZANIA, RWANDA. TO DATE, PEERLINC HAS TRAINED MORE THAN 50 COUNTRIES AROUND THE WORLD. G-TEC - AN INITIATIVE OF PEERLINC, G-TEC (GLOBAL TB EXPERT CONSULTATION) IS A DIGITAL ADVISORY PLATFORM CONNECTING FRONT-LINE PROVIDERS MANAGING DIFFICULT DR-TB CASES WITH EXPERTS ACROSS 18 COUNTRIES-TYPICALLY TURNING AROUND PRACTICAL GUIDANCE WITHIN 24 HOURS. LIFT-TB (LEVERAGING INNOVATION FOR FASTER TREATMENT OF TB) - THIS ACCESS PROGRAM, LAUNCHED IN 2020, SEEKS TO INCREASE TREATMENT COMPLETION RATES FOR DRUG-RESISTANT TB THROUGH ADOPTION AND SCALE UP OF NEW REGIMENS, BEGINNING WITH BPAL. IT FOCUSES ON SEVEN HIGH-BURDEN SOUTHEAST AND CENTRAL ASIAN COUNTRIES THAT SHOULDER APPROXIMATELY 1 IN 5 OF THE GLOBAL TB CASES. AS OF 2024, MORE THAN 100 COUNTRIES HAVE PROCURED THE SIX-MONTH, ALL-ORAL BPAL REGIMEN TO TREAT MORE THAN 180,000 PEOPLE WITH DRUG-RESISTANT TB. IN 2026, A NEW INDEPENDENT ANALYSIS SHOWED THAT LIFT-TB PLAYED A CRUCIAL ROLE IN ACCELERATING THE GLOBAL UPTAKE OF SHORTER, MORE EFFECTIVE TREATMENTS FOR DR-TB. THIS PROGRESS CONTRIBUTED TO A BROADER SHIFT IN HOW NEW TB TREATMENTS ARE INTRODUCED, HELPING REDUCE THE TIME FROM APPROVAL TO WIDESPREAD ACCESS FROM THE TYPICAL 7-9 YEARS TO APPROXIMATELY THREE YEARS. FAST TRACK THE CURE - IN SUPPORT OF THE WORLD HEALTH ORGANIZATION'S CALL TO ACTION TO ACCELERATE ACCESS TO SHORTER DR-TB CURES FOR ALL, THE FAST TRACK THE CURE MOVEMENT BRINGS COMMUNITIES AROUND THE WORLD TOGETHER TO RAISE AWARENESS AND FACILITATE ACCESS TO NEW DR-TB TREATMENTS, WHILE RAMPING UP ADVOCACY TO TELL WORLD LEADERS THAT SIX-MONTH DR-TB CURES MUST BE WIDELY ADOPTED AND AVAILABLE TO ALL WHO NEED THEM. FAST TRACK THE CURE IS ALSO COLLABORATING CLOSELY WITH STOP TB TO ENSURE STRATEGIC ALIGNMENT AND PARTNERSHIP AND WITH THE CHALLENGE FACILITY FOR CIVIL SOCIETY MOVEMENT, BY ALIGNING WITH THEIR COMMUNITY ENGAGEMENT, CAPACITY BUILDING, AND DEMAND CREATION PILLARS AND FOCUS. SLASH-TB - TB ALLIANCE AND THE SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE HAVE DEVELOPED SLASH-TB (SAVINGS FROM LEVERAGING & ADOPTING SHORTER & HIGHLY EFFECTIVE TB TREATMENTS), A MODEL TO ESTIMATE COST SAVINGS FOR HEALTH SERVICE SYSTEMS, PATIENTS, FAMILIES, AND/OR CAREGIVERS WHEN USING THE BPAL/M REGIMENS AS COMPARED TO STANDARD DRUG-RESISTANT TB TREATMENTS. UPSKILL TB -TB ALLIANCE, IN COLLABORATION WITH THE RPRI FOUNDATION AND INDONESIA'S MINISTRY OF HEALTH, HAS OFFICIALLY LAUNCHED THE UNIVERSAL PLATFORM FOR SKILL IMPROVEMENT AND LEARNING FOR NEW TB REGIMENS (UPSKILL TB) TO STRENGTHEN HEALTHCARE CAPACITY AND ACCELERATE THE FIGHT AGAINST DRUG-RESISTANT TUBERCULOSIS (DR-TB). THE LAUNCH EVENT TOOK PLACE IN JAKARTA AND WAS SHORTLY FOLLOWED BY A WORKSHOP LAUNCH AT THE 2025 UNION WORLD CONFERENCE ON LUNG HEALTH IN COPENHAGEN. UPSKILL TB IS A FLEXIBLE, AFFORDABLE, AND ACCESSIBLE DIGITAL LEARNING PLATFORM THAT HELPS ENSURE THAT HEALTHCARE PROFESSIONALS ACROSS INDONESIA, INCLUDING THOSE IN REMOTE REGIONS, ARE PREPARED TO DELIVER QUALITY CARE AND SUPPORT FOR PEOPLE UNDERGOING TREATMENT WITH NEW DR-TB REGIMENS. THE PLATFORM WILL BE ROLLED OUT TO ADDITIONAL COUNTRIES, INCLUDING UKRAINE AND CHINA IN 2026. MANAGE-TB - LAUNCHED AT THE 2025 UNION WORLD CONFERENCE ON LUNG HEALTH IN COPENHAGEN, MANAGE-TB IS A CLINICAL DECISION SUPPORT SYSTEM THAT HELPS PUBLIC AND PRIVATE CLINICIANS DELIVER GUIDELINE-ALIGNED CARE FOR COMPLEX DR-TB CASES, REDUCING VARIATION AND IMPROVING OUTCOMES. MANAGE-TB WAS BUILT BY TB ALLIANCE'S PARTNERS IN INDIA, AND THE TB ALLIANCE TEAM IS WORKING ON A NEW PROGRAM CALLED REGI-LINC THAT WILL HELP PROVIDE THIS SUPPORT SYSTEM MORE GLOBALLY. REGI-LINC IS ESTIMATED TO LAUNCH IN 2026.
FORM 990, PART VI, LINE 11B REVIEW OF FORM 990 BY GOVERNING BODYFORM 990 WAS PREPARED BY A NATIONALLY RECOGNIZED ACCOUNTING FIRM IN CONJUNCTION WITH THE ORGANIZATION'S FINANCE DEPARTMENT. THE DRAFT OF FORM 990 WAS REVIEWED BY THE ORGANIZATION'S FINANCE DEPARTMENT AND SENIOR MANAGEMENT, AND THEN PROVIDED TO ALL MEMBERS OF THE BOARD OF DIRECTORS IN DRAFT VIA ELECTRONIC MAIL, WITH AN OPPORTUNITY FOR THEM TO COMMENT OR MAKE INQUIRY BEFORE IT WAS FILED WITH THE INTERNAL REVENUE SERVICE.
FORM 990, PART VI, LINE 12C CONFLICT OF INTEREST POLICYTHE ORGANIZATION'S CONFLICT OF INTEREST POLICY IS DISTRIBUTED TO OFFICERS AND DIRECTORS ANNUALLY ALONG WITH A QUESTIONNAIRE THAT IS COMPLETED BY ALL OFFICERS AND DIRECTORS IN WHICH THEY ARE ASKED TO DISCLOSE INFORMATION REGARDING ACTUAL OR POTENTIAL CONFLICTS OF INTEREST. THESE QUESTIONNAIRES ARE COLLECTED AND REVIEWED ANNUALLY TO ENSURE COMPLIANCE WITH THE CONFLICT OF INTEREST POLICY. THE POLICY ITSELF ALSO REQUIRES ANY DIRECTOR OR OFFICER TO PROMPTLY DISCLOSE ANY CONFLICT OF INTEREST. INTERESTED DIRECTORS AND OFFICERS ARE REQUIRED TO RECUSE THEMSELVES FROM ANY DECISION ON MATTERS IN WHICH THEY HAVE AN INTEREST, AND SUCH RECUSAL IS NOTED IN THE MINUTES.
FORM 990, PART VI, LINE 15A PROCESS TO ESTABLISH COMPENSATION OF TOP MANAGEMENT OFFICIALTHE COMPENSATION COMMITTEE, WHICH CONSISTS OF TWO INDEPENDENT BOARD MEMBERS, ANNUALLY REVIEWS THE CEO COMPENSATION IN CONJUNCTION WITH AN EVALUATION OF ORGANIZATIONAL PERFORMANCE. THE COMMITTEE RECOMMENDS ADJUSTMENTS IN COMPENSATION TO THE FULL BOARD FOR REVIEW AND APPROVAL, WITHIN THE CONTEXT OF AN AGREED UPON COMPETITIVE POSITION. THE COMPETITIVENESS OF COMPENSATION IS PERIODICALLY BENCHMARKED USING INDEPENDENT SALARY SURVEY DATA FROM THE NOT-FOR-PROFIT AND FOR-PROFIT INDUSTRY. THE COMPENSATION COMMITTEE DOCUMENTATION INCLUDES THE PERFORMANCE ASSESSMENT, COMPARABLE DATA AND THE SOURCE OF THIS DATA, AND THE RECOMMENDED ADJUSTMENTS. THE MINUTES OF THE FULL BOARD INCLUDE DOCUMENTATION OF THE APPROVED DECISIONS. THE MINUTES OF THE BOARD AND COMMITTEE ARE PREPARED BEFORE THE LATER OF THE NEXT MEETING OR 60 DAYS AFTER THE FINAL DECISION OF THE BOARD AND THE COMMITTEE.
FORM 990, PART VI, LINE 15B PROCESS TO ESTABLISH COMPENSATION OF OTHER EMPLOYEESTHE COMPENSATION COMMITTEE, WHICH CONSISTS OF TWO INDEPENDENT BOARD MEMBERS, ANNUALLY REVIEWS OFFICERS COMPENSATION IN CONJUNCTION WITH AN EVALUATION OF ORGANIZATIONAL PERFORMANCE. THE COMMITTEE RECOMMENDS ADJUSTMENTS IN COMPENSATION TO THE FULL BOARD FOR REVIEW AND APPROVAL, WITHIN THE CONTEXT OF AN AGREED UPON COMPETITIVE POSITION. THE COMPETITIVENESS OF COMPENSATION IS PERIODICALLY BENCHMARKED USING INDEPENDENT SALARY SURVEY DATA FROM THE NOT-FOR-PROFIT AND FOR-PROFIT INDUSTRY. THE COMPENSATION COMMITTEE DOCUMENTATION INCLUDES THE PERFORMANCE ASSESSMENT, COMPARABLE DATA AND THE SOURCE OF THIS DATA, AND THE RECOMMENDED ADJUSTMENTS. THE MINUTES OF THE FULL BOARD INCLUDE DOCUMENTATION OF THE APPROVED DECISIONS. THE MINUTES OF THE BOARD AND COMMITTEE ARE PREPARED BEFORE THE LATER OF THE NEXT MEETING OR 60 DAYS AFTER THE FINAL DECISION OF THE BOARD AND THE COMMITTEE.
FORM 990, PART VI, LINE 19 REQUIRED DOCUMENTS AVAILABLE TO THE PUBLICTHE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST.
FORM 990, PART IX, LINE 11G OTHER FEES FOR SERVICESPROFESSIONAL SERVICES AND AGREEMENTS INCLUDE INDIVIDUAL CONSULTANTS WHO ARE CONTRIBUTING THEIR SPECIFIC EXPERTISE RELATED TO OUR CLINICAL TRIALS AND OTHER EARLY STAGE AND PRECLINICAL DISCOVERY WORK. EXPERTISE IN SUCH AREAS AS PHARMACOVIGILANCE, NON-GLP BIOANALYSIS, ANALYTICAL EVALUATION OF DRUG STABILITY AND PROGRAM MANAGEMENT ARE SOME OF THE SERVICES REQUIRED IN ORDER TO COMPLETE OUR SCIENTIFIC RESEARCH AND DEVELOPMENT. THESE CONSULTANTS ARE MANAGED BY OUR STAFF, WHO COORDINATE THE WORK NECESSARY TO BE COMPLETED AMONG ALL OUTSIDE PARTIES.
FORM 990, PART IX, LINE 11G OTHER FEESOTHER PROFESSIONAL FEES - TOTAL EXPENSE: 6327742, PROGRAM SERVICE EXPENSE: 5823234, MANAGEMENT AND GENERAL EXPENSES: 294800, FUNDRAISING EXPENSES: 209708;
FORM 990, PART XI, LINE 9 OTHER CHANGES IN NET ASSETS OR FUND BALANCESFOREIGN TRANSLATION LOSS - -44421; TOTAL - -44421;

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.